CANF Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Can Fite Biopharma Ltd (CANF) is not a strong buy at the moment for a beginner investor with a long-term focus. The technical indicators show a bearish trend, and the company's financial performance reflects declining revenues and negative earnings. While there are positive developments in clinical trials, the lack of significant trading trends, weak financials, and absence of strong proprietary trading signals suggest holding off on investment for now.
The technical indicators for CANF show a bearish trend. The MACD is below 0 and negatively contracting, indicating weak momentum. The RSI is neutral at 36.701, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 3.411, with resistance at 3.667 and support at 3.155.
Positive developments in clinical trials, including a Phase 2a study meeting its safety endpoint and a patient with advanced hepatocellular carcinoma remaining cancer-free for over nine years post-treatment.
and rising R&D expenses. Negative EPS of -$5.97 for FY
Lack of significant trading trends from insiders or hedge funds.
For FY 2025, revenues dropped by 38.8% YoY to $0.41 million, and R&D expenses increased to $6.69 million. The company reported a net income of -$1.65 million for Q4 2023, with an EPS of -4.29. Gross margin remained at 100%.
No recent analyst ratings or price target updates available.
